Oncology Research

 
Stock Quotes for Oncology Research top ^
  • Industry: Biotechnology
  • Sector: Healthcare
  • Stock Type: Speculative Growth
Sign-up for csbr investment picks
  • Industry: Biotechnology
  • Sector: Healthcare
  • Stock Style: Large Growth
  • Stock Type: Speculative Growth
Sign-up for csbr investment picks
  • Industry: Biotechnology
  • Sector: Healthcare
  • Stock Style: Small Core
  • Stock Type: Speculative Growth
Sign-up for ziop investment picks
  • Industry: Diagnostics & Research
  • Sector: Healthcare
  • Stock Type: Distressed
Sign-up for avto investment picks
  • Industry: Biotechnology
  • Sector: Healthcare
  • Stock Style: Small Growth
  • Stock Type: Distressed
Sign-up for clvs investment picks
  • Industry: Biotechnology
  • Sector: Healthcare
  • Stock Style: Small Core
  • Stock Type: Speculative Growth
Sign-up for ziop investment picks
  • Industry: Biotechnology
  • Sector: Healthcare
  • Stock Style: Small Growth
  • Stock Type: Distressed
Sign-up for clvs investment picks
  • Industry: Medical Care
  • Sector: Healthcare
  • Stock Type: Distressed
Sign-up for roix investment picks

 
News Articles for Oncology Research top ^
Foundation Medicine, Inc. (NASDAQ: FMI) today announced the presentation of new data from its ongoing collaboration with Clovis Oncology (NASDAQ: CLVS) to develop a novel companion diagnostic test to identify patients who have the potential to benefit from rucaparib, Clovis Oncology's poly (ADP-ribose) polymerase inhibitor (PARPi). These new data suggest that Foundation Medicine’s novel companion diagnostic can identify both BRCA-mutant patients and non BRCA-mutant patients who are more likely to benefit from rucaparib than patients who are biomarker negative.
Sign-up for Foundation Medicine’s Novel Companion Diagnostic Test, Developed in Collaboration with Clovis Oncology, Identifies Expanded Subgroup of Cancer Patients with the Potential to Respond to Clovis Oncology’s PARP inhibitor, Rucaparib investment picks
Clovis Oncology, Inc. (NASDAQ: CLVS) announced today that they have entered into a clinical trial collaboration with GlaxoSmithKline LLC to evaluate a novel combination therapy targeting mutant epidermal growth factor receptor (EGFR) non-small cell lung cancer (NSCLC). The Phase 1/2 trial of rociletinib given in combination with trametinib is planned to start in 1H 2015.
Sign-up for Clovis Oncology Enters into Oncology Clinical Trial Collaboration with GlaxoSmithKline investment picks
Clovis Oncology , Inc. (NASDAQ:CLVS) reported financial results for its third quarter ended September 30, 2014, and provided an update on the Company’s clinical development programs for the rest of 2014.
Sign-up for Clovis Oncology Announces Third Quarter 2014 Operating Results investment picks
The state of West Virginia has approved the Certificate of Need (CON) filed by the Charleston Area Medical Center (CAMC), Charleston Radiation Therapy Consultants, and Alliance Oncology, a division of Alliance HealthCare Services—enabling the joint venture to assume management and operations of the department of radiation therapy at the CAMC Cancer Center.
Sign-up for Charleston Area Medical Center and Alliance Oncology Receive State Approval for New Radiation Therapy Department investment picks
Clovis Oncology, Inc. (NASDAQ: CLVS) announced today that the Phase 2 portion of the seamless Phase 2/3 TIGER-1 ( T hird-Generation I nhibitor of Mutant E G FR in Lung Canc er ) study has commenced with the dosing of the first patient at a U.S. study site.
Sign-up for Clovis Oncology Announces First Patient Enrolled in TIGER-1 Study investment picks
Clovis Oncology, Inc. (NASDAQ: CLVS) announced today that its global Phase 2 study of lucitanib in patients with FGFR1-amplified squamous non-small cell lung cancer (NSCLC) has commenced and the first patient has been dosed at a U.S. study site.
Sign-up for Clovis Oncology Announces First Patient Enrolled in Lucitanib Phase 2 Study in Squamous Non-small Cell Lung Cancer investment picks
STAMFORD, Conn., Sept.
Sign-up for Loxo Oncology Announces Second Quarter 2014 Financial Results investment picks
AVEO Oncology (NASDAQ:AVEO) today announced poster presentations for two Phase 2 clinical studies of tivozanib, one in metastatic colorectal cancer (mCRC) and one in renal cell carcinoma (RCC), at the 2014 Congress of the European Society for Medical Oncology (ESMO), taking place September 25–30 in Madrid, Spain.
Sign-up for AVEO Oncology Announces Results from Phase 2 Clinical Studies of Tivozanib in Patients with Advanced Colorectal and Kidney Cancers Presented at ESMO 2014 Congress investment picks
Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its third quarter 2014 financial results on Thursday, November 6, 2014, after the close of the U.S. financial markets.
Sign-up for Clovis Oncology to Announce Third Quarter 2014 Financial Results and Host Webcast Conference Call on November 6 investment picks
Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that Patrick J.
Sign-up for Clovis Oncology to Present at the 2014 Credit Suisse Healthcare Conference investment picks
AVEO Oncology (NASDAQ:AVEO) today announced that clinical data on ficlatuzumab, the Company’s hepatocyte growth factor (HGF) inhibitory antibody, as well as tivozanib, the Company’s inhibitor of vascular endothelial growth factor (VEGF) 1, 2, and 3 receptors, will be presented at the European Society of Medical Oncology (ESMO) 2014 Congress in Madrid, Spain, September 26 – September 30, 2014.
Sign-up for Clinical Data on AVEO Oncology’s Ficlatuzumab and Tivozanib to Be Presented at the ESMO 2014 Congress investment picks

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Oncology Research
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry |  Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry

Previous: On-Year Growth  |  Next: One Holding